发布求助
文献互助 智能选刊 最新文献

HIV therapy最新文献

筛选
英文 中文
HIV Therapy merges with Future Virology HIV治疗与未来病毒学相结合
HIV therapy Pub Date : 2010-12-14 DOI: 10.2217/HIV.10.57
Elisa Manzotti, S. Cleghorn
{"title":"HIV Therapy merges with Future Virology","authors":"Elisa Manzotti, S. Cleghorn","doi":"10.2217/HIV.10.57","DOIUrl":"https://doi.org/10.2217/HIV.10.57","url":null,"abstract":"","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"6 1","pages":"613-613"},"PeriodicalIF":0.0,"publicationDate":"2010-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74241205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lymph node involution, T-cell adaptation and T-cell death in HIV infection. HIV感染中的淋巴结退化、t细胞适应和t细胞死亡。
HIV therapy Pub Date : 2010-12-14 DOI: 10.2217/HIV.10.56
I. Picerno, G. Visalli, R. Lentile, G. Piedimonte
{"title":"Lymph node involution, T-cell adaptation and T-cell death in HIV infection.","authors":"I. Picerno, G. Visalli, R. Lentile, G. Piedimonte","doi":"10.2217/HIV.10.56","DOIUrl":"https://doi.org/10.2217/HIV.10.56","url":null,"abstract":"Fibrotic tissue involution occurs in a large variety of chronic diseases. As the final phase of follicular atrophy and depletion, a diffuse fibrosis is the more severe consequence of the chronic process of lymph node involution that characterizes HIV infection. This review focuses on the comparison between HIV-induced lymph node fibrosis and other chronic fibroproliferative diseases, in terms of cell types participating in the process and signaling intermediates that together cause the deposition of collagen and remodel normal tissue architecture. Given that the histological quantification of this type of fibrosis cannot be easily introduced as a routine method in clinical pathology, we will discuss the possibility of exploiting some functional modifications, which express the adaptation of T cells to the fibrotic/hypoxic environment, as biochemical markers of the evolution of lymph node damage.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"41 1","pages":"629-637"},"PeriodicalIF":0.0,"publicationDate":"2010-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90789422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The intersection between HIV and syphilis in men who have sex with men: some fresh perspectives. 男男性行为者中艾滋病毒和梅毒的交叉:一些新的观点。
HIV therapy Pub Date : 2010-12-14 DOI: 10.2217/HIV.10.55
F. Drummond, R. Guy, J. Kaldor, B. Donovan
{"title":"The intersection between HIV and syphilis in men who have sex with men: some fresh perspectives.","authors":"F. Drummond, R. Guy, J. Kaldor, B. Donovan","doi":"10.2217/HIV.10.55","DOIUrl":"https://doi.org/10.2217/HIV.10.55","url":null,"abstract":"Syphilis is increasing in men who have sex with men and disproportionately affects HIV-infected men. Here we review the epidemiology, diagnostic techniques, treatment guidelines, follow-up procedures and control of syphilis. The difference in these factors in HIV-infected men and uninfected men and evidence for this is reviewed. We explain that HIV-infected men are at higher risk of syphilis acquisition as a result of different behavioral factors. Thus, some control strategies may be different for HIV-infected men owing to these factors and also because HIV-infected men are more closely linked with medical care. There is no strong evidence to suggest there should be any differences in diagnostic techniques, treatment guidelines or follow-up procedures between HIV-infected and uninfected men.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"3 1","pages":"661-673"},"PeriodicalIF":0.0,"publicationDate":"2010-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75012394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Switching antiretroviral therapy to minimize metabolic complications. 转换抗逆转录病毒治疗以减少代谢并发症。
HIV therapy Pub Date : 2010-11-01 DOI: 10.2217/hiv.10.47
Jordan E Lake, Judith S Currier
{"title":"Switching antiretroviral therapy to minimize metabolic complications.","authors":"Jordan E Lake, Judith S Currier","doi":"10.2217/hiv.10.47","DOIUrl":"10.2217/hiv.10.47","url":null,"abstract":"<p><p>Advances in HIV therapy have made living with HIV for decades a reality for many patients. However, antiretroviral therapy has been associated with multiple long-term complications, including dyslipidemia, fat redistribution, insulin resistance and increased cardiovascular risk. As newer agents with improved metabolic profiles have become available, there is growing interest in the safety and efficacy of switching ART as a strategy to reduce long-term complications. This article reviews recently published data on switching ART to minimize the contributions of specific agents to these complications.</p>","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"4 6","pages":"693-711"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236090/pdf/nihms269059.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30327350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV-related cryptococcal meningitis in resource-limited settings 在资源有限的环境中与hiv相关的隐球菌脑膜炎
HIV therapy Pub Date : 2010-10-25 DOI: 10.2217/HIV.10.46
A. Chirianni, V. Esposito
{"title":"HIV-related cryptococcal meningitis in resource-limited settings","authors":"A. Chirianni, V. Esposito","doi":"10.2217/HIV.10.46","DOIUrl":"https://doi.org/10.2217/HIV.10.46","url":null,"abstract":"Cryptococcal infection remains a significant problem in patients with AIDS in resource-limited settings. Even with the availability of HAART, the 6-month rate of survival after cryptococcal meningitis (CM) reported by several epidemiological studies is very low. The worldwide number of infections and deaths due to CM appears similar to those for diseases that have received greater public health attention. In sub-Saharan Africa, deaths due to CM may be more frequent than TB. However, in many developing countries the capacity to perform the complicated management of severe CM is limited and CM mortality may remain a problem in Africa, and also in areas where antiretroviral therapy is available, as late presentation with advanced disease is common and consequently IRIS is becoming an emerging problem. A focused effort to improve diagnostic capacity, expand treatment options, and identify effective measures for the prevention of cryptococcal disease is urgently required.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"17 1","pages":"567-576"},"PeriodicalIF":0.0,"publicationDate":"2010-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90719447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The impact of baseline characteristics on virologic response to etravirine: 48-week pooled analysis of DUET-1 and DUET-2 基线特征对依曲维林病毒学反应的影响:对DUET-1和DUET-2的48周汇总分析
HIV therapy Pub Date : 2010-10-25 DOI: 10.2217/HIV.10.41
P. Cahn, R. Haubrich, C. Katlama, F. Goebel, F. Suter, M. Peeters, J. Vingerhoets, R. Sinha, J. Witek
{"title":"The impact of baseline characteristics on virologic response to etravirine: 48-week pooled analysis of DUET-1 and DUET-2","authors":"P. Cahn, R. Haubrich, C. Katlama, F. Goebel, F. Suter, M. Peeters, J. Vingerhoets, R. Sinha, J. Witek","doi":"10.2217/HIV.10.41","DOIUrl":"https://doi.org/10.2217/HIV.10.41","url":null,"abstract":"Aims: The impact of baseline characteristics on response to the non-nucleoside reverse transcriptase inhibitor etravirine was investigated at 48 weeks in the Phase III DUET trials. Methods: Logistic regression was used to examine the effect of baseline demographics, disease characteristics and characteristics of antiretroviral therapy on virologic response (viral load <50 HIV-1 RNA copies/ml) to etravirine in pre-specified pooled subgroup analyses. Results: Several nondemographic characteristics were significant predictors of response in univariate analyses. Baseline viral load, adherence to study medication and use of enfuvirtide were predictive of response in the multivariate analysis. Patients treated with etravirine consistently achieved higher response rates than placebo-treated patients. Conclusions: The clinical benefits of etravirine in the DUET trials were observed irrespective of baseline characteristics.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"150 1","pages":"605-610"},"PeriodicalIF":0.0,"publicationDate":"2010-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77434863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Politics and policy in HIV/AIDS: the road ahead for South Africa 艾滋病毒/艾滋病的政治和政策:南非的前进道路
HIV therapy Pub Date : 2010-10-25 DOI: 10.2217/HIV.10.34
H. Coovadia
{"title":"Politics and policy in HIV/AIDS: the road ahead for South Africa","authors":"H. Coovadia","doi":"10.2217/HIV.10.34","DOIUrl":"https://doi.org/10.2217/HIV.10.34","url":null,"abstract":"Professor Hoosen Coovadia is currently working on maternal, newborn and child health, in metropolitan Durban at MatCH. He is personally and professionally committed to justice, democracy, development and freedom, during and after apartheid. He was chairperson of the Mandela government’s first Commission on Maternal and Child Health to design appropriate policies for South Africa. He has headed the largest International AIDS Conferences to be brought to South Africa and published more than 320 papers on maternal and child health in national and international journals. He publicly and consistently opposed former South African President Thabo Mbeki’s administration on their controversial AIDS policies, which denied HIV/AIDS patients antiretroviral treatment.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"144 1","pages":"527-530"},"PeriodicalIF":0.0,"publicationDate":"2010-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86018722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninfectious HIV-related comorbidities and HAART toxicities: choosing alternative antiretroviral strategies 非传染性hiv相关合并症和HAART毒性:选择替代性抗逆转录病毒策略
HIV therapy Pub Date : 2010-10-25 DOI: 10.2217/HIV.10.44
L. Gazzola, C. Tincati, A. Monforte
{"title":"Noninfectious HIV-related comorbidities and HAART toxicities: choosing alternative antiretroviral strategies","authors":"L. Gazzola, C. Tincati, A. Monforte","doi":"10.2217/HIV.10.44","DOIUrl":"https://doi.org/10.2217/HIV.10.44","url":null,"abstract":"In the HAART era, clinicians are faced with the challenge of treating an aging HIV-infected population increasingly affected by severe comorbidities, which may compromise the tolerability of antiretroviral regimens. In this special population, it is imperative for physicians to carefully tailor antiretroviral treatment in order not to worsen patients’ underlying clinical conditions and to achieve both tolerability and immune–virologic efficacy. This article aims to explore the impact of standard HAART regimens on the different noninfectious HIV-related comorbidities: metabolic, cardiovascular, bone and renal diseases, in order to provide tools to fit the most appropriate antiretroviral combination according to individual clinical conditions. Clinical experience with alternative antiretroviral strategies, avoiding nucleoside reverse transcriptase inhibitor toxicities and involving new antiretroviral classes, will be reviewed to obtain an overview on future perspectives.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"24 1","pages":"553-565"},"PeriodicalIF":0.0,"publicationDate":"2010-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74282311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Immune reconstitution inflammatory syndrome in HIV-positive patients: a relatively new and not fully understood phenomenon 艾滋病毒阳性患者的免疫重建炎症综合征:一个相对较新的和尚未完全了解的现象
HIV therapy Pub Date : 2010-10-25 DOI: 10.2217/HIV.10.45
G. Arendt, T. Nolting
{"title":"Immune reconstitution inflammatory syndrome in HIV-positive patients: a relatively new and not fully understood phenomenon","authors":"G. Arendt, T. Nolting","doi":"10.2217/HIV.10.45","DOIUrl":"https://doi.org/10.2217/HIV.10.45","url":null,"abstract":"The article describes the immune reconstitution inflammatory syndrome in HIV-positive patients as a phenomenon detected in recent years as a consequence of HAART initiation in patients with a severely compromised immune system and rapid improvement under HAART. Pathophysiology, clinical presentation and therapeutic options are discussed.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"124 1","pages":"577-587"},"PeriodicalIF":0.0,"publicationDate":"2010-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79502371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
HIV treatment in the criminal justice system 刑事司法系统中的艾滋病毒治疗
HIV therapy Pub Date : 2010-10-25 DOI: 10.2217/HIV.10.43
M. Milloy, E. Wood
{"title":"HIV treatment in the criminal justice system","authors":"M. Milloy, E. Wood","doi":"10.2217/HIV.10.43","DOIUrl":"https://doi.org/10.2217/HIV.10.43","url":null,"abstract":"The advent of HAART has resulted in a dramatic decline in HIV-related morbidity and mortality among those accessing HIV treatment [1]. Fortunately, efforts to simplify regimens and scale up treatment systems have led to individuals being engaged in treatment in numbers and locales that were unimaginable just 10 years ago. Still, some seropositive populations have not benefited equally from advancements in HIV treatment. Studies of HIV-seropositive individuals who use injection drugs (IDU) on HAART confirm that adherent individuals can derive similar benefits as adherent individuals from other risk groups [2]. Nevertheless, coverage of HAART among IDU remains low, not only in areas such as the Russian Federation and other countries of the former Soviet Union and China, where a substantial and increasing proportion of new infections are linked to injection drug use, but also in settings with advanced healthcare systems [3]. Once on HAART, HIVseropositive IDU often achieve lower levels of adherence and are more likely to prematurely discontinue therapy [4,5]. As a result of the individual and, likely, community [6] benefits of attracting and maintaining IDU on HAART, there is an urgent need to identify and remove barriers to access and adherence to HAART among IDU [7].","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"3 1","pages":"519-522"},"PeriodicalIF":0.0,"publicationDate":"2010-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86336240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信